
    
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study to
      evaluate the safety and tolerability of the combination of GSK573719 (500mcg) Inhalation
      Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder
      inhaler (Novel DPI) over 28 days in subjects with COPD
    
  